natgillin/translations-raw huggingface dataset:
Inaktiveret poliovirus type 3 ...................................................................
Inactivated type 3 poliovirus ..................................................................
Inaktiveret porcin parvovirus, stamme NADL-2 ....................................................
Inactivated porcine parvovirus, strain NADL-2, .....................................................
Inaktiveret Porcin Parvovirus, stamme NADL-2 .....................................................
Inactivated porcine parvovirus, strain NADL-2, .....................................................
Inaktiveret porcin parvovirus, stamme NADL-2 .......................................................
Inactivated porcine parvovirus, strain NADL-2, .......................................................
Inaktiveret porcin parvovirus, stamme NADL-2 RP > 1,15
Inactivated porcine parvovirus, strain NADL-2: RP* > 1.15,
Inaktiveret porcint circovirus type 2 (PCV2) ................................................ ≥ 1,8 log10 ELISA-enheder
Inactivated porcine circovirus type 2 (PCV2) .................................................  1.8 log10 ELISA Units
Inaktiveret rabiesvirus, stamme SAD Vnukovo-32 ≥ 2,0 IU***
Inactivated rabies virus, strain SAD Vnukovo-32 ≥ 2.0 IU
Inaktiveret rekombinant aviær influenza virus, af subtypen H5N3 (stamme rg-A/ck/VN/C58/04) >1:40 HI1 enheder
Inactivated recombinant avian influenza virus of H5N3 subtype (strain rg-A/ck/VN/C58/04) ) > 1:40 HI Units Water in oil adjuvant
Inaktiveret rekombinant aviær influenza virus, af subtypen H5N3 (stamme rg-A/ck/VN/C58/04) >1:40 HI1 enheder Vand i olie adjuvans
Inactivated recombinant avian influenza virus of H5N3 subtype (strain rg-A/ck/VN/C58/04) > 1:40 HI Units Water in oil adjuvant
Inaktiveret rekombinant Porcint Circovirus type 1 som Porcint Circovirus type 2 ORF-protein 1,6 ≤ RP ≤ 5,3
Inactivated recombinant Porcine Circovirus type 1 expressing the Porcine Circovirus type 2 ORF2 protein 1.6  RP  5.3
Inaktiveret RHDV2, stamme V-1037: ≥70% cELISA40
Inactivated RHDV2, strain V-1037: ≥70% cELISA40
Inaktiveret Schmallenberg-virus (RP ≥ 1/dosis)
Inactivated Schmallenberg virus (RP ≥ 1/dose)
Inaktiveret stamme af Bordetella pertussis**  4 IU Hepatitis B virus overflade antigen rekombinant** (S protein)*** 10 mikrogram Haemophilus influenzae type b polysaccharid (polyribosylribitolfosfat) 2 2,5 mikrogram
Inactivated Bordetella pertussis strain**  4 IU Hepatitis B virus surface antigen recombinant** (S protein)*** 10 micrograms
Inaktiveret Vestnilvirus, stamme VM-2
Inactivated West Nile virus, strain VM-2.
Inaktiveret Vestnilvirus, stamme VM-2 (1,0 – 2,2 RP)
Inactivated West Nile virus, strain VM-2 (1.0–2.2 RP).
Inaktiveret Vestnilvirus, stamme VM-2 RP* 1,0- 2,2
Inactivated West Nile virus, strain VM-2 RP* 1.0–2.2
Inaktiveret viral vaccine til stimulation af aktiv immunitet mod bluetonguevirus serotype 8.
Inactivated viral vaccine, to stimulate active immunity against bluetongue virus serotype 8.
Inaktiveret, rekombinant kimært porcint circovirus type 1 med porcint circovirus type 2 ORF2-protein
Inactivated recombinant chimeric porcine circovirus type 1containing the porcine circovirus type 2 ORF2 protein
Incidencen af akutte afstødningsepisoder var væsentligt lavere hos patienter behandlet med basiliximab og tre-stofs- lægemiddel immunsuppressiv behandling.
The incidence of acute rejection episode was substantially lower in patients receiving basiliximab and a triple drug immunosuppressive regimen.
Incidencen af anæmi var øget, når ambrisentan blev givet i kombination med tadalafil (bivirkningshyppighed 15 %) sammenlignet med incidencen af anæmi, når ambrisentan og tadalafil blev givet som monoterapi (henholdsvis 7 % og 11 %).
The incidence of anaemia was increased when ambrisentan was dosed in combination with tadalafil (15% adverse event frequency), compared to the incidence of anaemia when ambrisentan and tadalafil were given as monotherapy (7% and 11%, respectively).
Incidens af anormale laboratorieværdier i TT01 og TT02 (n=80 patienter)
Incidence of laboratory abnormalities in TT01 and TT02 (n=80 patients)
Incidens ved baseline n (%)a
Incidence at Baseline n (%)a
Incidens- rate for PHN per 1000 personår
Incidence rate of PHN per 1,000 person years
Incidens- rate for zoster per 1.000 personår
Incidence rate of zoster per 1,000 person years
Incidensdensitet 95 % CI
Rate ratio 95% CI
Incidensen af alle bivirkninger relateret til lever- og galdesystemerne var < 1,5 % i alle behandlingsgrupper og ens med placebo.
The incidence of all adverse events relating to liver and biliary systems was  1.5% in any treatment group and similar to placebo.
Incidensen af alvorlige bivirkninger i forbindelse med depression og selvmordstanker var sammenlignelig og lav (< 1 %) for gruppen med Plegridy 125 mikrogram hver 2. uge og gruppen med placebo.
The incidence of serious events related to depression and suicidal ideation were similar and low (<1%) in both Plegridy 125 micrograms every 2 weeks and placebo-treated patients.
Incidensen af alvorlige infektioner var 0,03 pr. patientår hos Trudexa-behandlede patienter og 0,03 pr. patientår hos placebo- og aktiv kontrolbehandlede patienter.
The incidence of serious infections was 0.03 per patient year in Trudexa treated patients and 0.03 per patient year in placebo and active control−treated patients.
Incidensen af bekræftede tilfælde af pankreatitis var 0,3% i sitagliptin-armen, og 0,2% i placebo-armen.
The incidence of adjudication-confirmed pancreatitis events was 0.3 % in sitagliptin-treated patients and 0.2 % in placebo-treated patients.
Incidensen af bivirkninger af mindst moderat intensitet (≥ grad 2) var højere i INCIVO-gruppen end i placebogruppen.
The incidence of adverse drug reactions (ADRs) of at least moderate intensity (≥ Grade 2) was higher in the INCIVO group than in the placebo group.
Incidensen af bivirkninger af sværhedsgrad 3 eller 4 er højere hos patienter med moderat nedsat nyrefunktion (creatininclearance 30 – 50 ml/min ved baseline), sammenlignet med den samlede population.
The incidence of grade 3 or 4 adverse reactions in patients with moderate renal impairment (creatinine clearance 30-50 ml/min at baseline) is increased compared to the overall population.
Incidensen af bivirkninger af sværhedsgrad 3 eller 4 er højere hos patienter med moderat nyreinsufficiens (creatininclearance 30 – 50 ml/min ved baseline), sammenlignet med den samlede population.
The incidence of grade 3 or 4 adverse reactions in patients with moderate renal impairment (creatinine clearance 30-50 ml/min at baseline) is increased compared to the overall population.
Incidensen af bivirkninger blev evalueret for de patienter, som fik ≤ 6 serier af pemetrexed- vedligeholdelsesbehandling (N = 519), og sammenlignet med de patienter, som fik > 6 serier pemetrexed (N = 281).
The incidence of adverse reactions was evaluated for patients who received ≤ 6 cycles of pemetrexed maintenance (N = 519), and compared to patients who received > 6 cycles of pemetrexed (N = 281).
Incidensen af bivirkninger blev evalueret for de patienter, som fik ≤ 6 serier af pemetrexed- vedligeholdelsesbehandling (n=519), og sammenlignet med de patienter, som fik >6 serier pemetrexed (n=281).
The incidence of adverse reactions was evaluated for patients who received ≤6 cycles of pemetrexed maintenance (N=519), and compared to patients who received >6 cycles of pemetrexed (N=281).
Incidensen af bivirkninger blev evalueret for de patienter, som fik ≤6 serier af pemetrexed vedligeholdelsesbehandling (N=519), og sammenlignet med de patienter, som fik >6 serier pemetrexed (N=281).
The incidence of adverse reactions was evaluated for patients who received ≤ 6 cycles of pemetrexed maintenance (N=519), and compared to patients who received > 6 cycles of pemetrexed (N=281).
Incidensen af bivirkninger blev evalueret for de patienter, som fik ≤6 serier af pemetrexed- vedligeholdelsesbehandling (N = 519), og sammenlignet med de patienter, som fik > 6 serier pemetrexed (N = 281).
The incidence of adverse reactions was evaluated for patients who received ≤ 6 cycles of pemetrexed maintenance (N=519), and compared to patients who received > 6 cycles of pemetrexed (N=281).
Incidensen af bivirkninger blev evalueret for de patienter, som fik ≤6 serier af pemetrexed- vedligeholdelsesbehandling (N=519), og sammenlignet med de patienter, som fik >6 serier pemetrexed (N=281).
The incidence of adverse reactions was evaluated for patients who received ≤ 6 cycles of pemetrexed maintenance (N = 519), and compared to patients who received > 6 cycles of pemetrexed (N = 281).
Incidensen af bivirkninger blev evalueret for de patienter, som fik ≤6 serier af pemetrexed- vedligeholdelsesbehandling (N=519), og sammenlignet med de patienter, som fik >6 serier pemetrexed (N=281).
The incidence of adverse reactions was evaluated for patients who received ≤ 6 cycles of pemetrexed maintenance (N=519), and compared to patients who received > 6 cycles of pemetrexed (N=281).
Incidensen af bivirkninger blev evalueret for de patienter, som fik ≤6 serier af pemetrexed-vedligeholdelsesbehandling (n=519), og sammenlignet med de patienter, som fik >6 serier pemetrexed (n=281).
The incidence of adverse reactions was evaluated for patients who received ≤ 6 cycles of pemetrexed maintenance (N=519), and compared to patients who received > 6 cycles of pemetrexed (N=281).
Incidensen af brændende følelse i huden var højere i gruppen der blev behandlet med tacrolimus end i hydrocortisongruppen.
The incidence of local skin burning was higher in the tacrolimus treatment groups than in the hydrocortisone group.
Incidensen af brændende følelse i huden var højere i gruppen der blev behandlet med tacrolimus end i hydrokortison gruppen.
The incidence of local skin burning was higher in the tacrolimus treatment groups than in the hydrocortisone group.
Incidensen af cytopeni hang imidlertid også tydeligt sammen med sygdomsstadiet, idet hyppighed af 3. eller
However, the occurrence of cytopenias was also clearly dependent on the stage of the disease, the frequency of grade 3 or 4 neutropenias (ANC < 1.0 x 109/l) and thrombocytopenias (platelet
Incidensen af cytopeni hang imidlertid også tydeligt sammen med sygdomsstadiet, idet hyppighed af 3. eller
However, the occurrence of cytopenias was also clearly dependent on the stage of the disease, the frequency of grade 3 or 4neutropenias (ANC <1.0x109/1) and thrombocytopenias (platelet count
Incidensen af cytopeni hang imidlertid også tydeligt sammen med sygdomsstadiet, idet hyppighed af 3. eller 4. grads neutropeni (ANC <1,0 x 109/l) og thrombocytopenias (platelet count < 50 x 109/l) var 4–6 gange højere ved blastkrise og accelereret fase (59–64 % og 44–63 % for henholdsvis neutropeni og trombopeni) end ved sammenligning med nydiagnosticerede patienter med kronisk fase CML (16,7 % neutropeni og 8,9 % trombocytopeni).
However, the occurrence of cytopenias was also clearly dependent on the stage of the disease, the frequency of grade 3 or 4 neutropenias (ANC < 1.0 x 109/L) and thrombocytopenias (platelet count < 50 x 109/L) being between 4 and 6 times higher in blast crisis and accelerated phase (59–64% and 44–63% for neutropenia and thrombocytopenia, respectively) as compared to newly diagnosed patients in chronic phase CML (16.7% neutropenia and 8.9% thrombocytopenia).
Incidensen af cytopeni hang imidlertid også tydeligt sammen med sygdomsstadiet, idet hyppighed af 3. eller 4. grads neutropeni (ANC <1,0 x 109/l) og trombocytopeni (trombocyttal <50 x 109/l) var 4–6 gange højere ved blastkrise og accelereret fase (59–64% og 44–63% for henholdsvis neutropeni og trombopeni) end ved sammenligning med nydiagnosticerede patienter med kronisk fase CML (16,7% neutropeni og 8,9% trombocytopeni).
However, the occurrence of cytopenias was also clearly dependent on the stage of the disease, the frequency of grade 3 or 4 neutropenias (ANC < 1.0 x 109/l) and thrombocytopenias (platelet count < 50 x 109/l) being between 4 and 6 times higher in blast crisis and accelerated phase (59-64% and 44-63% for neutropenia and thrombocytopenia, respectively) as compared to newly diagnosed patients in chronic phase CML (16.7% neutropenia and 8.9% thrombocytopenia).
Incidensen af DAGT serokonversion hos patienter, der fik ceftolozan/tazobactam, var 0,2% i de kliniske studier.
The incidence of DAGT seroconversion in patients receiving ceftolozane/tazobactam was 0.2% in the clinical trials.
Incidensen af disse bivirkninger er relateret til den indgivne dosis, patientens alder og muligvis omvendt relateret til patientens alder ved vækshormonmanglens start.
The incidence of these adverse reactions is related to the administered dose, the age of patients, and possibly inversely related to the age of patients at the onset of growth hormone deficiency.
Incidensen af diverticulitis var sammenlignelig på tværs af behandlingsgrupperne hos postmenopausale kvinder eller mænd med osteoporose og hos kvinder, der var i behandling med en aromatasehæmmer på grund af ikke-metastatisk brystcancer.
The incidence of diverticulitis was comparable between treatment groups in postmenopausal women or men with osteoporosis and in women undergoing aromatase inhibitor therapy for nonmetastatic breast cancer.
Incidensen af frakturer blev evalueret som et sikkerhedsendepunkt.
Fracture incidence was evaluated as a safety endpoint.
Incidensen af frakturer var 8 for zoledronsyre-behandlede patienter versus 7 for risedronatbehandlede patienter (p=0,8055).
The incidence of fractures was 8 for zoledronic acid- treated patients versus 7 for risedronate-treated patients (p=0.8055).
Incidensen af grad 4 neutropeni varende 7 dage eller mere var 22 %.
The incidence of Grade 4 neutropenia lasting 7 days or more was 22 %.
Incidensen af hypoglykæmi i gruppen, som blev behandlet med sitagliptin , var signifikant lavere end i glipizidgruppen (4,9% versus 32,0%).
The incidence of hypoglycaemia in the sitagliptin group (4.9 %) was significantly lower than that in the glipizide group (32.0 %).
Incidensen af hæmatologisk respons var 70 % med en varighed på 2–3 måneder.
The rate of haematological response was 70 % with a duration of 2–3 months.
Incidensen af hæmatologisk respons var 70 % med en varighed på 2–3 måneder.
The rate of haematological response was 70% with a duration of 2–3 months.
Incidensen af hæmatologisk respons var 70% med en varighed på 2–3 måneder.
The rate of haematological response was 70% with a duration of 2-3 months.
Incidensen af hæmatologisk respons var 70% med en varighed på 2–3 måneder.
The rate of haematological response was 70% with a duration of 2–3 months.
Incidensen af ikke-CABG-relateret TIMI større blødning, inklusive livstruende og letale blødninger, samt TIMI mindre blødning var statistisk signifikant højere hos de forsøgspersoner, der blev behandlet med prasugrel sammenlignet med clopidogrel hos UA/NSTEMI- og Total AKS-populationerne.
The incidence of Non-CABG-related TIMI major bleeding, including life-threatening and fatal, as well as TIMI minor bleeding, was statistically significantly higher in subjects treated with prasugrel compared to clopidogrel in the UA/NSTEMI and All ACS populations.
Incidensen af ikke-melanom hudkræft var 0,49 pr.
The incidence of non-melanoma skin cancer was 0.49 per
Incidensen af infusionsrelaterede reaktioner i efterfølgende infusioner var sammenlignelige i de 2 behandlingsarme og blev lavere for hver behandlingsserie.
The incidence of IRRs in subsequent infusions was comparable in both arms and decreased with each cycle.
Incidensen af infusionsrelaterede reaktioner var 65% ved infusionen af de første 1000 mg Gazyvaro (20% af patienterne oplevede en infusionsrelateret reaktion af grad 3-5; der blev ikke indberettet dødelige bivikninger).
The incidence of IRRs was 65% with the infusion of the first 1,000 mg of Gazyvaro (20% of patients experiencing a Grade 3-5 IRR, with no fatal events reported).
Incidensen af infusionsrelaterede symptomer aftager væsentligt ved de følgende infusioner og er under 1 % efter 8 doser MabThera.
The incidence of infusion-related symptoms decreases substantially with subsequent infusions and is less than 1 % after eight doses of MabThera.
Incidensen af kardiovaskulære hændelser var dog ens mellem linagliptingruppen og placebogruppen (1,03 % med linagliptin vs 1,35 % med placebo).
However, cardiovascular events were similar between linagliptin and placebo (1.03% with linagliptin versus 1.35% with placebo).
Incidensen af kardiovaskulære hændelser var dog ens mellem linagliptingruppen og placebogruppen (1,03 % med linagliptin vs 1,35 % med placebo).
However, CV events were similar between linagliptin and placebo (1.03% with linagliptin vs 1.35% with placebo).
Incidensen af kliniske frakturer, herunder vertebrale og non-vertebrale frakturer samt hoftefrakturer, blev bedømt i 2.127 mænd og kvinder i alderen 50-59 år (gennemsnitsalder 74,5 år) med en nylig (inden for 90 dage) lavenergi-hoftefraktur, som blev fulgt i gennemsnitligt 2 år på studiemedicin.
The incidence of clinical fractures, including vertebral, non-vertebral and hip fractures, was evaluated in 2,127 men and women aged 50-95 years (mean age 74.5 years) with a recent (within 90 days) low- trauma hip fracture who were followed for an average of 2 years on study medication.
Incidensen af krampeanfald var lav og sammenlignelig mellem patienter, som fik Plegridy (125 mikrogram hver 2. uge) og placebo (<1 % i hver gruppe).
The incidence of seizure events was low and comparable in patients receiving Plegridy (125 micrograms every 2 weeks) and placebo (<1% in each group).
Incidensen af laktatacidose kan og skal reduceres ved også at vurdere andre associerede risikofaktorer såsom dårligt kontrolleret diabetes, ketose, langvarig faste, stort alkoholindtag, leverinsufficiens og alle tilstande forbundet med hypoksi.
The incidence of lactic acidosis can and should be reduced by also assessing other associated risk factors such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic insufficiency and any conditions associated with hypoxia.
Incidensen af nogle dopaminerge bivirkninger, såsom hallucinationer, dyskinesi og perifere ødemer, er generelt højere i kombination med levodopa hos patienter med Parkinsons sygdom.
The incidence of some dopaminergic adverse reactions, such as hallucinations, dyskinesia, and peripheral oedema generally is higher when given in combination with L-dopa in Parkinson’s patients.
Incidensen af ONJ, justeret for patientår, var 0,2% i det første år af behandling og 1,7% i det andet år.
The patient year adjusted incidence of ONJ was 0.2% during the first year of treatment and 1.7% in the second year.
Incidensen af post-dosis-symptomer, der opstår inden for de første tre dage efter administration af Zoledronsyre Teva Pharma, kan reduceres ved at administrere paracetamol eller ibuprofen kort efter administration af Zoledronsyre Teva Pharma.
The incidence of post-dose symptoms occuring within the first three days after administration of Zoledronic acid Teva Pharma can be reduced with the administration of paracetamol or ibuprofen shortly following Zoledronic acid Teva Pharma administration
Incidensen af potentielt klinisk signifikante fald i lymfocyttal (<0,5 x 109/l) (<1 %), neutrofiltal (≤1,0 x 109/l) (<1 %) og trombocyttal (≤100 x 109/l) (≤1 %) var sammenlignelig mellem patienter, som fik Plegridy, og patienter, som fik placebo.
The incidence of potentially clinically significant decreases in lymphocyte counts (<0.5 x 109/L) (<1%), neutrophil counts (≤1.0 x 109/L) (<1%) and platelet counts (≤100 x 109/L) (≤1%) was similar in Plegridy-treated patients compared to placebo-treated patients.
Incidensen af resistens over for caspofungin ved forskellige kliniske isolater af Candida og Aspergillus er sjælden.
The incidence of resistance to caspofungin by various clinical isolates of Candida and Aspergillus is rare.
Incidensen af sene ALAT- forhøjelser blev ikke påvirket af behandlingsvarigheden.
The incidence of late ALT elevations was not affected by treatment duration.
Incidensen af systemiske bivirkninger efter topisk oftalmisk administration er lavere end ved systemisk administration.
Incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration.
Incidensen af tilbagefald under den 6-måneders dobbeltblinde follow-up periode var 14 % for Xeristar og 42 % for placebo.
The incidence of relapse during the 6- months double-blind follow-up period was 14% for Xeristar and 42% for placebo.
Incidensen af tilbagefald under den 6-måneders dobbeltblinde followup periode var 14 % for Cymbalta og 42 % for placebo.
The incidence of relapse during the 6- months double-blind follow-up period was 14% for Cymbalta and 42% for placebo.
Incidensen af trombocytopeni var højere i Gazyvaro plus chlorambucil-armen (15%) sammenlignet med rituximab plus chlorambucil-armen, særligt i den første behandlingsserie.
The incidence of thrombocytopenia was higher in the Gazyvaro plus chlorambucil arm (15%) compared to the rituximab plus chlorambucil arm especially during the first cycle.
Incidensen af trombocytopeni var lavere i Gazyvaro plus bendamustin-armen (15%) sammenlignet med armen med bendamustin alene (24%).
The incidence of thrombocytopenia was lower in the Gazyvaro plus bendamustine (G+B) arm (15%) compared to the bendamustine (B) alone arm (24%).
Incidensen af udslæt og alvorlige kutane reaktioner
Incidence of rash and severe cutaneous reactions
Incidensen for blødninger hos patienter, der får den anbefalede behandling for DVT eller PE med normal nyrefunktion eller mild, moderat eller svær nedsættelse af nyrefunktionen var henholdsvis 3,0 % (34/1132), 4,4 % (32/733), 6,6 % (21/318) og 14,5 % (8/55).
Incidences of bleeding events in patients receiving the recommended regimen in the treatment of DVT or PE with normal renal function, mild renal impairment, moderate renal impairment and severe renal impairment were 3.0 % (34/1,132), 4.4 % (32/733), 6.6% (21/318), and 14.5 % (8/55) respectively.
Incidensen og alvorligheden af bivirkninger relateret til centralnervesystemet og mave-tarm- kanalen aftog i reglen med tiden.
Incidence and severity of central nervous system (CNS) and gastrointestinal (GI) adverse reactions usually decreased over time.
Incidenserne er angivet nedenfor:
The incidences are presented below:
Incidenslysdosen er 20 J/cm2, leveret med mikrolinse-fiberoptik i et rundt felt på en tumoroverflade med en irradians på 100 mW/cm2, hvilket betyder en belysningstid på 200 sekunder.
The incident light dose is 20 J/cm2, delivered by the microlens fibre-optic in a circular field to the tumour surface at an irradiance of 100 mW/cm2, implying an illumination time of 200 seconds.
Incidensraten af nye infektionstilfælde i placebokontrollerede kliniske studier med reumatoid artritis var 1,03 pr. patientår for alle patienter, som fik Cimzia, og 0,92 pr. patientår for alle patienter, som fik placebo.
The incidence rate of new cases of infections in placebo-controlled clinical trials in rheumatoid arthritis was 1.03 per patient-year for all Cimzia-treated patients and 0.92 per patient-year for placebo-treated patients.
INCIVO 1.125 mg hver 12. time sammen med pegyleret interferon-alfa-2a 180 g/uge og ribavirin 1.000 eller 1.200 mg/dag
INCIVO 1,125 mg every 12 hours with peginterferon alfa-2a 180 g/week and ribavirin 1,000 or 1,200 mg/day
INCIVO 1.125 mg hver 12. time sammen med pegyleret interferon-alfa-2b 1,5 g/kg/uge og ribavirin 800 eller 1.200 mg/dag
INCIVO 1,125 mg every 12 hours with peginterferon alfa-2b 1.5 g/kg/week and ribavirin 800 or 1,200 mg/day
INCIVO 750 mg hver 8. time sammen med pegyleret interferon-alfa-2b 1,5 g/kg/uge og ribavirin 800 eller 1.200 mg/dag
INCIVO 750 mg every 8 hours with peginterferon alfa-2b 1.5 g/kg/week and ribavirin 800 or 1,200 mg/day
INCIVO anbefales ikke til børn og unge under 18 år, da sikkerhed og virkning ikke er klarlagt hos denne population.
INCIVO is not recommended for use in children and adolescents younger than 18 years of age because the safety and efficacy has not been established in this population.